4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H22BrN5O2
Molecular Weight	516.389
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of 4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide

Structure Search

SMILES

CC1=NC2=C(C=C(CN(CC#C)C3=CC=C(C=C3)C(=O)NCC4=CC=CN=C4)C(Br)=C2)C(=O)N1

InChI

InChIKey=SHNBLWMBWXIKMR-UHFFFAOYSA-N

InChI=1S/C26H22BrN5O2/c1-3-11-32(16-20-12-22-24(13-23(20)27)30-17(2)31-26(22)34)21-8-6-19(7-9-21)25(33)29-15-18-5-4-10-28-14-18/h1,4-10,12-14H,11,15-16H2,2H3,(H,29,33)(H,30,31,34)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20609415

CB30865 (ZM242421) is a potent inhibitor of Nampt, an enzyme present in the NAD biosynthetic pathway. CB30865 is highly potent against a variety of human tumour cell lines.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Nicotinamide phosphoribosyltransferase 8 Target ID: P43490 Gene ID: 10135.0 Gene Symbol: NAMPT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20609415	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20609415	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action.	1998 Sep 1	9725559

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Growth inhibitory potency was determined after continuous exposure of cells to CB30865 for 48 h (L1210), 72 h (W1L2), or 96 h (CH1) followed by Coulter Counting (L1210 and W1L2) or 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) assay. CB30865 inhibited tumor growth with IC50 values in the 1-10 nM range.

Name

Type

Language

4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide

Systematic Name

English

Benzamide, 4-[[(7-bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)-

Systematic Name

English

4-((7-Bromanyl-2-methyl-4-oxidanylidene-3H-quinazolin-6-yl)methyl-prop-2-ynyl-amino)-N-(pyridin-3-ylmethyl)benzamide

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID70432117

Created by admin on Sat Dec 16 20:09:58 GMT 2023 , Edited by admin on Sat Dec 16 20:09:58 GMT 2023

PRIMARY

PUBCHEM

135528987

Created by admin on Sat Dec 16 20:09:58 GMT 2023 , Edited by admin on Sat Dec 16 20:09:58 GMT 2023

PRIMARY

CAS

206275-15-2

Created by admin on Sat Dec 16 20:09:58 GMT 2023 , Edited by admin on Sat Dec 16 20:09:58 GMT 2023

PRIMARY

FDA UNII

QH8386GD3S

Created by admin on Sat Dec 16 20:09:58 GMT 2023 , Edited by admin on Sat Dec 16 20:09:58 GMT 2023

PRIMARY

SUBSTANCE RECORD


					QH8386GD3S

4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20609415

Originator

Approval Year

Targets

Conditions

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20609415